Aptevo Therapeutics Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity
Reuters
Jun 18
Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 1b/2 Trial Results for Mipletamig in Frontline AML, Achieving 85% Remission Rate Without Added Toxicity
SEATTLE, WA / ACCESS Newswire / June 18, 2025 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company in the clinical development stage, has announced new clinical data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia $(AML.AU)$ patients unfit for intensive chemotherapy. Results show an 85% remission rate among evaluable patients and a strong safety profile, with no dose-limiting toxicities observed. These findings suggest that mipletamig could significantly enhance standard AML treatment. The trial is nearing full enrollment for its third cohort at the highest dose level evaluated. The results were presented as part of the ongoing study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040816) on June 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.